SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brad C. Dunlap who wrote (52)9/28/1996 4:15:00 PM
From: Rick Costantino   of 1762
 
Your post was filled with some interesting information. Your
estimate of the cost of treatment agrees with what I have seen.
I was not aware that of Coulter's treatment (waht drug, and in what
Phase of clinical testing?) being more efficacious
than IDEC's C2B8. I do know that the oncology community has recieved
C2B8 with extreme enthusiasm. IMO, we are on a real breakthough
here. And consider that when C2B8 is tested earlier on (remember
in the trials, these are largely patients who have already not responded
to chemo and/or radiotherapy and have advanced disease) it will most
likely be even more effective.

I agree that monoclonals is where it is at for the future of
biotecehnology. IDEC's patent of primatized antibodies alone
makes it worth being a stockholder.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News